• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Israel·Healthcare·BCUR.TA
Share

Erika Carmel-Tech Ltd Stocks

ILA 21.6Last Updated 10.11.2025

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

ILA 55824.26311

ILA 21.6
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly undervalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Erika Carmel-Tech Ltd, an Israeli company founded in Haifa in 2007, operates globally in the medical technology sector. Formerly known as Erika B-Cure Laser Ltd until its name change in October 2025, the company is dedicated to the development, manufacturing, marketing, distribution, and sale of its B-Cure laser product line. Their offerings include the B-Cure Laser Classic, a secure and non-invasive medical device engineered for home use to alleviate both chronic and acute pain. Another key product is the B-Cure Laser Pro, a non-invasive and safe medical instrument that has received clinical validation for its effectiveness in treating a range of sudden onset and long-term conditions. These B-Cure laser therapies address a wide array of ailments. This extensive list includes Achilles tendon inflammation, burns, carpal tunnel syndrome, pain in finger joints, fibromyalgia, hip pain, discomfort following dental procedures, lower and upper back pain, neck pain, shoulder pain, knee pain, tennis elbow, other general joint pain, temporomandibular joint disorders, and various wounds.

Company Valuation

Greatly undervalued
7/7

From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks. Specifically, the stock is underpriced on P/FCF.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.06.2026 07:00

An analyst called the sell-off following SpaceX's IPO excessive. Which stocks did he recommend?

16.06.2026 04:40

SpaceX shares surged 20% on the second day of trading. What investors should watch next

16.06.2026 03:34

Nvidia to raise $25 billion in its first bond offering in five years — Reuters

16.06.2026 01:21

Dow hits record high and Nasdaq posts its best day since March: Market rallies on US-Iran deal

16.06.2026 00:25

TD Cowen expects Micron's stock to rise by more than 50%. What new growth driver has the bank identified?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026